What the data shows is It's worth noting that I find it compelling that Shortly after the opening bell, we will be selling 25 s of Eli Lilly at roughly $782.
Ing the trade, Jim Cramer's Charitable Trust will own 100 s of LLY, decreasing its weighting to roughly 2, in today's financial world. 20% from 2 (fascinating analysis).
We're locking in big fits on our Eli Lilly position ing disappointing news from Novo Nordisk, its main competitor in the GLP-1 market.
Novo Nordisk s are plunging more than 20% on Tuesday after the company slashed its 2025 sales growth outlook to the range of 8% to 14% from 13% to 21%.
This significant revision was driven by lower expectations for its obesity drug Wegovy and diabetes drug Ozempic in the U (something worth watching).
Market, as well as lower-than-expected penetration for Wegovy in other. What the re reveals is company attributed the U (this bears monitoring), in light of current trends.
Weakness to the use of compounded GLP-1s, slower-than-expected market expansion and competition. Eli Lilly s are down in sympathy with these results.
Meanwhile, Some of this makes sense, and some of it doesn't, in today's market environment. Novo Nordisk citing increased competition is actually a positive sign for Eli Lilly.
On the other hand, Additionally, It means Lilly is continuing to gain. However, the slower-than-expected market expansion is a concerning signal to us, in this volatile climate.
The continued use of compounded GLP-1s is a negative too, considering recent developments. Eli Lilly and Novo Nordisk are two different companies.
Eli Lilly has the superior GLP-1s, it will have an oral medication apved early next year, and has been a leader in manufacturing capacity (remarkable data).
Novo Nordisk has been in disarray for a year, struggling with supply constraints, battling the compounders Hims & Hers, and losing to Lilly.
Furthermore, Novo fired its CEO in May and named internal candidate Maziar Mike Doustdar as its new chief Tuesday.
While it's possible that Novo's outlook cut is unique to the company and Eli Lilly is doing much better, we simply don't want to take that chance ahead of Lilly's earnings report on Aug (noteworthy indeed).
Moreover, However, 7 That's why we are taking fits on Tuesday and downgrading our rating to a 2. We'll look to revisit our rating when we get better visibility into the second half of the year.
From this sale, we will realize a strong gain of around 220% on stock purchased in January 2022. On the other hand, (Jim Cramer's Charitable Trust is long LLY, in this volatile climate.
See here for a full list of the stocks. Furthermore, ) As a r to the CNBC with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio, given current economic conditions.
If Jim has talked a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.
THE ABOVE INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, TOGETHER WITH OUR DISCLAIMER.
NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION VIDED IN CONNECTION WITH THE. Nevertheless, NO SPECIFIC OUTCOME OR FIT IS GUARANTEED.